Skip to main content
. 2022 Feb 17;13:826337. doi: 10.3389/fimmu.2022.826337

Figure 5.

Figure 5

(A) K-M plots showed that different CDCA4 levels were associated with pathological stages of OS, PFS, DFS, RFS, DMFS, PSS, DSS and FP events; (B) The results of survival analysis of multiple cancers were integrated into the meta-analysis, and the combined results showed that high expression of CDCA4 in cancer patients was significantly associated with poor prognosis.